Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience

References

• Hasford J, Pfirrmann M, Hochhaus A. How long will chronic myeloid leukemia patients treated with imatinib mesylate live? Leukemia. 2005;19(4):497–499.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Strom SS, O'Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186-93–e193.
   PubMed Web of Science ®Google Scholar
• Höglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94(Suppl 2):S241–S7.
   PubMed Web of Science ®Google Scholar
• Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29(6):1336–1343.
   PubMed Web of Science ®Google Scholar
• Castagnetti F, Gugliotta G, Baccarani M, et al. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol. 2015;26(1):185–192.
   PubMed Web of Science ®Google Scholar
• Zhou L, You JH, Wu W, et al. Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor. Leuk Res. 2013;37(10):1216–1221.
   PubMed Web of Science ®Google Scholar
• Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol. 2007;27(4):241–243.
   PubMed Web of Science ®Google Scholar
• He K, Lago MW, Iyer RA, et al. Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metab Dispos. 2008;36(12):2564–2570.
   PubMed Web of Science ®Google Scholar
• Apperley J. Issues of imatinib and pregnancy outcome. J Natl Compr Canc Netw. 2009;7(10):1050–1058.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Abruzzese E, Chelysheva E, et al. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015;90(12):1111–1115.
   PubMed Web of Science ®Google Scholar
• Tybulewicz VL, Crawford CE, Jackson PK, et al. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 1991;65(7):1153–1163.
   PubMed Web of Science ®Google Scholar
• Soriano P. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev. 1994;8(16):1888–1896.
   PubMed Web of Science ®Google Scholar
• Soriano P. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development. 1997;124(14):2691–2700.
   PubMed Web of Science ®Google Scholar
• Mauduit C, Hamamah S, Benahmed M. Stem cell factor/c-kit system in spermatogenesis. Hum Reprod Update. 1999;5(5):535–545.
   PubMed Web of Science ®Google Scholar
• Hoch RV, Soriano P. Roles of PDGF in animal development. Development. 2003;130(20):4769–4784.
   PubMed Web of Science ®Google Scholar
• Bleyl SB, Moshrefi A, Shaw GM, et al. Candidate genes for congenital diaphragmatic hernia from animal models: sequencing of FOG2 and PDGFRalpha reveals rare variants in diaphragmatic hernia patients. Eur J Hum Genet. 2007;15(9):950–958.
   PubMed Web of Science ®Google Scholar
• Ault P, Kantarjian H, O'Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006;24(7):1204–1208.
   PubMed Web of Science ®Google Scholar
• Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111(12):5505–5508.
   PubMed Web of Science ®Google Scholar
• Abruzzese E, Trawinska MM, Perrotti AP, et al. Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis. 2014;6(1):e2014028.
   PubMedGoogle Scholar
• Kantarjian HM, Talpaz M, O'Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002;8(7):2177–2187.
   PubMed Web of Science ®Google Scholar
• Milojkovic D, Apperley JF. How I treat leukemia during pregnancy. Blood. 2014;123(7):974–984.
   PubMed Web of Science ®Google Scholar
• Apperley J. CML in pregnancy and childhood. Best Pract Res Clin Haematol. 2009;22(3):455–474.
   PubMed Web of Science ®Google Scholar
• Abruzzese E, Trawinska MM, de Fabritiis P, et al. Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol. 2016;9(8):781–791.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Pregnancy outcomes in patients treated with bosutinib. Blood. 2018;132(Supplement 1):1729.
   PubMedGoogle Scholar
• Gnessi L, Basciani S, Mariani S, et al. Leydig cell loss and spermatogenic arrest in platelet-derived growth factor (PDGF)-A-deficient mice. J Cell Biol. 2000;149(5):1019–1026.
   PubMed Web of Science ®Google Scholar
• Prasad AM, Ramnarayan K, Nalini K, et al. Effect of imatinib on the biochemical parameters of the reproductive function in male Swiss albino mice. Indian J Pharmacol. 2011;43(4):389–392.
   PubMed Web of Science ®Google Scholar
• Seshadri T, Seymour JF, McArthur GA. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med. 2004;351(20):2134–2135.
   PubMed Web of Science ®Google Scholar
• Berman E, Druker BJ, Burwick R. Chronic Myelogenous Leukemia: pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2018;36(12):1250–1256.
   PubMed Web of Science ®Google Scholar
• Hochhaus A. Educational session: managing chronic myeloid leukemia as a chronic disease. Hematology Am Soc Hematol Educ Program. 2011;2011:128–135.
   PubMed Web of Science ®Google Scholar
• Laferla JJ. Spontaneous abortion. Clin Obstet Gynaecol. 1986;13(1):105–114.
   PubMedGoogle Scholar
• Bulletins—Gynecology CoP. The American College of Obstetricians and Gynecologists Practice Bulletin no. 150. Early pregnancy loss. Obstet Gynecol. 2015;125(5):1258–1267.
   PubMedGoogle Scholar
• Shah NP, Tran C, Lee FY, Chen P, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399–401.
   PubMed Web of Science ®Google Scholar
• Bhandari A, Rolen K, Shah BK. Management of chronic myelogenous leukemia in pregnancy. Anticancer Res. 2015;35(1):1–11.
   PubMed Web of Science ®Google Scholar
• Palani R, Milojkovic D, Apperley JF. Managing pregnancy in chronic myeloid leukaemia. Ann Hematol. 2015;94 Suppl 2 (Suppl 2):S167–S76.
   PubMedGoogle Scholar
• Law AD, Dong Hwan Kim D, Lipton JH. Pregnancy: part of life in chronic myelogenous leukemia. Leuk Lymphoma. 2017;58(2):280–287.
   PubMed Web of Science ®Google Scholar
• Bazarbashi MS, Smith MR, Karanes C, et al. Successful management of Ph chromosome chronic myelogenous leukemia with leukapheresis during pregnancy. Am J Hematol. 1991;38(3):235–237.
   PubMed Web of Science ®Google Scholar
• Strobl FJ, Voelkerding KV, Smith EP. Management of chronic myeloid leukemia during pregnancy with leukapheresis. J Clin Apheresis. 1999;14(1):42–44.
   PubMed Web of Science ®Google Scholar
• Jackson N, Shukri A, Ali K. Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy. Br J Haematol. 1993;85(1):203–204.
   PubMed Web of Science ®Google Scholar
• Celiloglu M, Altunyurt S, Undar B. Hydroxyurea treatment for chronic myeloid leukemia during pregnancy. Acta Obstet Gynecol Scand. 2000;79(9):803–804.
   PubMed Web of Science ®Google Scholar
• Baer MR, Ozer H, Foon KA. Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia. Br J Haematol. 1992;81(2):167–169.
   PubMed Web of Science ®Google Scholar
• Kuroiwa M, Gondo H, Ashida K, et al. Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy. Am. J. Hematol. 1998;59(1):101–102.
   PubMed Web of Science ®Google Scholar
• Baykal C, Zengin N, Coşkun F, et al. Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report. Eur J Gynaecol Oncol. 2000;21(1):89–90.
   PubMed Web of Science ®Google Scholar
• Yazdani Brojeni P, Matok I, Garcia Bournissen F, et al. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol. 2012;33(3):265–268.
   PubMed Web of Science ®Google Scholar
• Woo GH, Katayama K, Bak EJ, et al. Effects of prenatal hydroxyurea-treatment on mouse offspring. Exp Toxicol Pathol. 2004;56(1-2):1–7.
   PubMedGoogle Scholar
• Thauvin-Robinet C, Maingueneau C, Robert E, et al. Exposure to hydroxyurea during pregnancy: a case series. Leukemia. 2001;15(8):1309–1311.
   PubMed Web of Science ®Google Scholar
• Berveiller P, Andreoli A, Mir O, et al. A dramatic fetal outcome following transplacental transfer of dasatinib. Anticancer Drugs. 2012;23(7):754–757.
   PubMed Web of Science ®Google Scholar